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Abstract: Topiramate is an anticonvulsant drug used for the treatment of epilepsy and 
prophylaxis of migraine. Some authors have proposed its use as a mood stabilizer and have 
reported its efficacy in reducing impulsiveness and improving mood regulation, possibly via its 
antagonism to glutamatergic transmission in the lateral hypothalamus, although this indication 
is still controversial. Weight loss is a side effect consistently reported in the medical literature in 
patients treated with topiramate. Given its potential role in stabilizing mood and reducing impulse 
control problems and weight, topiramate has been proposed as a treatment for obese patients with 
binge eating disorder (BED). The aim of this paper is to review published data on the efficacy 
and safety of topiramate for the treatment of obese subjects with BED. Although the evidence is 
preliminary, topiramate appears to be a relatively safe and effective treatment for obese subjects 
with BED. Limitations of the studies and future directions for research are discussed.
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Introduction
Binge eating disorder (BED) has been the subject of an increasing number of recent 
studies; nevertheless, it is still awaiting official diagnostic recognition, and it is classi-
fied as a syndrome in need of further study in the most recent edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV-TR).
BED is characterized by recurrent episodes of binge eating (defined as the ingestion 
of a large quantity of food in a discrete period of time) accompanied by a subjective 
sense of loss of control over eating. Other criteria are distress about binge episodes; 
eating more rapidly than normal; eating until uncomfortably full; eating large amounts 
when not hungry; eating alone because of embarrassment; and feeling disgusted, 
depressed, or guilty about overeating. In a community survey, 5% of obese subjects 
met BED criteria, while 30% of patients participating in weight loss programs met 
BED criteria.1 It is probably the most frequent eating disorder,2 and it is associated with 
obesity and significant medical and psychiatric comorbidity (especially with regard to 
anger and personality issues).3–5 Some psychotropic medications have also been found 
to be associated with the induction of binge eating.6 These features, together with its 
chronic nature and its greater prevalence than anorexia and bulimia nervosa, suggest 
that it should be considered a public health problem of no less importance than the 
other two more established eating disorders.2
Despite a growing recognition of the consequences of BED on public health, 
substantive evidence on treatment approaches for the disorder is limited. A combination Neuropsychiatric Disease and Treatment 2009:5 386
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of pharmacological and behavioral strategies has been 
proposed.7 Research on the pharmacological treatment of 
BED has focused mostly on selective serotonin reuptake 
inhibitors (SSRIs) because BED shares some clinical features 
with bulimia nervosa. However, a recent meta-analysis8 has 
concluded that currently available data are not sufficient to 
formally recommend antidepressants as a first-line therapy 
for BED. The search for novel pharmacological treatments for 
BED is now focusing on other classes of drugs, particularly 
sibutramine and topiramate.9 Topiramate, which is approved 
for treatment of epilepsy and prophylaxis of migraine, 
has been shown consistently to reduce weight in several 
placebo-controlled obesity trials.10 It has also been shown 
to be effective in treating bulimia nervosa in a randomized 
controlled trial (RCT).11
Current knowledge about the mechanism by which 
topiramate reduces binge eating is not conclusive. Topiramate 
might have a specific effect in reducing food intake mediated 
by its antagonism to glutamatergic transmission in the 
lateral hypothalamus.12 Other possible mechanisms of action 
reviewed by McElroy and colleagues13 include directly 
inducing weight loss by stimulating energy expenditure, 
decreasing binge eating by altering the rewarding properties 
of food, and reducing general impulsivity.
The aim of this paper is to review available evidence on 
the efficacy/effectiveness and safety of topiramate in adults 
with BED.
Methods
We conducted a systematic search using the following 
computerized literature databases: PubMed, Medline, and 
PsychInfo. Search terms included “topiramate” and “binge,” 
“binge eating,” “obesity,” and “binge eating disorder.” 
The search in computerized bibliographic databases was 
complemented with journal hand-searching.
Given the limited number of studies available, we 
reviewed RCTs as well as case series and single case reports. 
The data presented cannot be synthesized with a systematic 
approach because of the lack of homogeneity among the 
studies examined; however, the breadth of the selection 
criteria allows for wide application of these data to different 
populations of patients with BED.
We restricted our evaluation to studies including adult 
obese subjects.
Literature review
The reviewed articles are summarized in Table 1. We 
first consider studies involving RCTs and then address 
those involving open labels. We included both kinds of 
studies in the belief that the effects of topiramate both 
under ideal conditions (efficacy studies such as RCTs) and 
routine clinical situations (effectiveness trials such as those 
reporting on the effects of topiramate as an add-on to other 
psychopharmacologic treatments) can contribute to treatment 
of this disorder.
Randomized controlled trials
A 14-week, double-blind, flexible dose (25 to 600 mg/day), 
placebo-controlled trial assessed the efficacy of topiramate 
in 61 obese [body mass index (BMI)  30] outpatients with 
BED (53 women, 8 men).14 The study sample consisted of 
patients aged 18 to 60 years who met DSM-IV-TR criteria for 
BED and had a score of 15 on the Yale–Brown Obsessive 
Compulsive Scale modified for binge eating (YBOCS-BE). 
Topiramate was administered at a dose of 100 to 600 mg/day 
depending on response to treatment. The primary efficacy 
measure was the number of binge eating episodes during the 
7 days before each visit. Secondary measures of efficacy were 
the number of days in which the patient had at least one binge 
during the 7 days before each visit, the Clinical and Global 
Impression improvement (CGI-I) and severity (CGI-S) 
scales, the YBOCS-BE, and the Hamilton Depression Rating 
Scale (HDRS or HAM-D). Physical measures included BMI, 
waist-to-hip ratio, and percent total body fat (measured by 
bioelectrical impedance). The median dose of topiramate 
was 212 mg/day (range 50 to 600). Statistical analyses 
were performed both as intention to treat (with the last 
observation carried forward) and as completer analysis. 
Fourteen of 30 patients in the topiramate group (46.7%) 
and 12 of 31 patients in the placebo group (38.7%) did not 
complete the 14 weeks of treatment. Among the causes for 
withdrawing from the study were adverse events (topiramate, 
n = 6, placebo, n = 3; mainly headache, paresthesia, 
amenorrhea, leg cramps, and sedation), lack of efficacy 
(topiramate, n = 1, placebo, n = 2), nonadherence to the study 
protocol (topiramate, n = 6; placebo, n = 7), and exacerbation 
of a preexisting medical condition (topiramate, n = 1). 
Patients receiving topiramate achieved greater reductions in 
binge frequency, which was the primary outcome measure, 
than those in the placebo group (94% vs 46%, respectively, 
P  0.002), as well as reductions in binge day frequency 
(93% vs 46%, P  0.02), CGI score (χ2 = 6.31, P = 0.01), 
weight loss (5.9 kg vs 1.2 kg), and reduction of body 
fat (reduction in percent body fat: χ2 = 7.87, P = 0.006; 
reduction in total body fat: χ2 = 10.68, P = 0.001). Limitations 
included the short study period and the high percentage of Neuropsychiatric Disease and Treatment 2009:5 387
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dropouts among the patients. The authors concluded that 
topiramate was effective in reducing binge eating behavior 
and weight.
The authors of the previous study performed a 42-week, 
open-label extension to assess the long-term efficacy, toler-
ability, and safety of topiramate in BED associated with 
obesity.15 This study will be discussed in this section because 
it represents the continuation of the previous study. Thirty-five 
patients completed the controlled study (topiramate, n = 15; 
placebo, n = 16); 31 of these were interested in pursuing 
open-label treatment with topiramate and were enrolled in 
the extension study. The primary endpoint was change from 
baseline to the final visit in weekly binge frequency using 
the last observation carried forward. Some patients received 
double-blind topiramate from the beginning of the controlled 
study; the outcome for this group was measured in terms of 
changes in binge frequency since the beginning of the study. 
Baseline binge frequency was defined as the frequency of 
bingeing at the beginning of treatment with topiramate for 
patients who received placebos in the double-blind period 
of the study. Topiramate was titrated from an initial dose of 
25 mg/day to a maximum dose of 600 mg/day, as needed, 
to achieve a reduction in binge frequency and as tolerated. 
Outcome measures considered were the same as for the 
double-blind trial. Efficacy analyses were performed on an 
intent-to-treat basis for all patients, with at least one efficacy 
evaluation after double-blind or open-label topiramate 
treatment. Forty-four patients received at least one dose of 
topiramate during the double-blind (n = 13) or open-label 
extension period (n = 31). One patient never returned for 
an evaluation after taking topiramate; thus 43 patients were 
included in the final analysis. The median duration of therapy 
among these patients was 23.5 weeks. Thirty-five patients 
discontinued topiramate during the controlled study (n = 14) 
or the extension trial (n = 21). The mean dose of topiramate 
administered was 342 ± 257 mg/day. Ten patients completed 
a total of 56 weeks of treatment. The intent-to-treat analysis 
revealed that patients treated with topiramate during either 
the controlled or extension studies achieved significant 
reductions in mean binge frequency (n = 43, –3.2, P  0.001), 
which were even more evident in patients who completed 
treatment (n = 10, –5.0, P = 0.002). Analysis of secondary 
outcomes showed significant reductions from baseline CGI-S 
scores (P  0.001), YBOCS-BE total scores (P  0.001), 
body weight (–6.0 kg, P  0.001), and BMI (–2.1 kg/m2, 
P  0.001). The mean Hamilton Rating Scale for Depression 
(HAM-D or HDRS) scores were not significantly reduced 
from baseline to the final visit. Fourteen of 44 patients 
discontinued topiramate because of adverse events. The 
most frequently reported adverse events were paresthesia 
(75% of patients), dry mouth (46%), headache (36%), taste 
disturbance (34%), cognitive problems (32%), dizziness 
(30%), somnolence (25%), fatigue (25%), dyspepsia (25%), 
diarrhea (21%), confusion (18%), nausea (18%), and 
nervousness (16%). Patients who discontinued topiramate 
because of adverse effects were not taking a higher dose 
than those who discontinued topiramate for other reasons 
(225 ± 179 vs 326 ± 282 mg/day). The severity of these 
adverse events was considered mild to moderate. The authors 
concluded that subjects with BED continued to experience 
a reduction in binge eating and had further weight loss with 
topiramate treatment during the open-label extension of the 
study. Limitations regarding the design of this study are the 
lack of a control group and randomization, and the fact that 
it was open-label; other limitations include the small sample 
size and the high attrition rate.
McElroy and colleagues13 investigated the safety and 
efficacy of topiramate in a 16-week, multicenter, randomized 
placebo-controlled trial. Patients were men and women 
between 18 and 65 years of age with a diagnosis of BED, 
having at least 3 binge days per week and a BMI of 30 to 
50 kg/m2. Patients with a history of bipolar disorder, psychotic 
disorder, substance abuse, current clinically significant 
depression, and those with a BMI  50 kg/m2 were 
excluded to reduce the rate of discontinuation attributable 
to decreased impulse control and poor health. Patients were 
randomized to receive topiramate (195 patients) or placebo 
(199 patients). The primary outcome measure was the number 
of binge eating days per week. Secondary outcome measures 
included binge eating episodes per week, body weight, BMI, 
CGI score, YBOCS-BE score, Barrat Impulsiveness Scale 
Version 11 (BIS-11), Three-Factor Eating Questionnaire 
(TFEQ), Hamilton Anxiety Scale (HAM-A), and Sheenan 
Disability Scale (SDS). The median dose of topiramate was 
300 mg (range 25 to 400 mg/day). Patients treated with 
topiramate achieved a significantly greater rate of reduction 
in binge eating days per week than those receiving placebo 
(from 4.6 to 0.9 vs from 4.6 to 2.2; χ2 = 51, P  0.001). 
Topiramate was also associated with a significantly greater 
improvement than placebo for binge eating episodes per 
week; body weight; BMI; CGI-S scores; total obsessive– 
compulsive scores of the YBOCS-BE scale; overall motor 
and non-planning impulsiveness scores of the BIS-11 scale; 
cognitive restraint, disinhibition, and hunger subscores of the 
TFEQ; and overall social and family life, and disability scores 
of the SDS. On the other hand, between-group differences Neuropsychiatric Disease and Treatment 2009:5 389
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were not found in the rate of change in the Montgomery 
Asberg Depression Rating Scale (MADRS), HAM-A, SDS 
school/work disability, or BIS-11 attentional impulsiveness 
scores. Fifty-eight percent of patients treated with topiramate 
achieved remission, whereas only 29% of patients treated 
with placebo remitted (P  0.001). Adverse events reported 
by more than 10% in the topiramate group were paresthesia, 
upper respiratory tract infection, taste disturbance, difficulty 
with concentration/attention, and difficulty with memory 
not otherwise specified. Most adverse events were mild 
to moderate in severity; the most common adverse events 
causing topiramate discontinuation were difficulty with 
memory not otherwise specified and depression. Twenty-nine 
(15%) discontinuations in the topiramate group were 
attributable to adverse events. Limitations of this study 
include the use of self-report measures, short study duration, 
risk that the blinding procedure might have been spoiled by 
the higher prevalence of adverse events in topiramate-treated 
patients compared to the placebo group, and exclusion 
of patients with Axis I psychiatric disorders, which may 
make it impossible to generalize the results of the study to 
patients with significant psychiatric comorbidity. The authors 
concluded that topiramate was efficacious and well tolerated 
in the treatment of obese patients with BED.
Claudino and colleagues16 evaluated the efficacy of 
adjunctive treatment with topiramate compared to that with 
placebo in reducing weight gain and binge eating in obese 
patients receiving cognitive behavior therapy (CBT). This 
study consisted of a 21-week double-blind, randomized, and 
placebo-controlled trial. The sample consisted of 73 adults 
aged 18 to 60 years (70 women, 3 men) with a BMI  30 kg/m2 
who met DSM-IV-TR criteria for BED and scored 17 or more 
on the Binge Eating Scale (BES). Patients were randomly 
assigned to receive topiramate or placebo with doses titrated 
to 200 mg/day. Doses were increased to a maximum of 
300 mg/day in patients who failed to achieve a reduction in 
baseline weight of at least 5% or a reduction in the number 
of days with binge episodes of at least 50%. Dose reductions 
were allowed for patients who did not tolerate their current 
doses. The primary outcome measure was weight change; 
secondary efficacy measures were BMI, binge frequency, 
BES scores, depressive symptoms (Beck Depression 
Inventory [BDI] scores), and treatment tolerance. At the end 
of the study period, the mean weight change was –6.8 kg in 
the topiramate group vs –0.9 kg in the placebo group. Patients 
randomized to topiramate showed a significantly greater 
rate of weight reduction (topiramate × time interaction) than 
patients assigned to the placebo group (χ2 = 16.1, P  0.001) 
and a final BMI of 35 ± 3.5 kg/m2, whereas those taking the 
placebo demonstrated a final BMI of 36.7 ± 4.7 kg/m2. The 
percent weight loss was also greater in topiramate-treated 
patients than in those receiving the placebo (6.8 ± 5.2% 
vs 4.1 ± 4.3%, P = 0.04). At the end of the trial, a greater 
percentage of patients receiving topiramate attained a weight 
loss of 10% compared to those receiving placebo (33.3% 
vs 11.5%; χ2 = 3.71, P = 0.05). No significant differences 
were found between treatment groups with regard to the 
rate of change in the number of binge days per week, the 
number of binge episodes per week, or BES scores. The rate 
of remission for binge eating in the intent-to-treat group was 
significantly higher among patients taking topiramate (83.8%) 
than among those taking placebo (61.1%). BDI scores were 
significantly reduced in both treatment groups but these 
changes did not reach statistical significance (P = 0.20). 
Seventeen patients (23.3% of  the sample) dropped out of 
treatment (7 in the topiramate group, 10 in the placebo group). 
The most frequent cause for withdrawing from treatment was 
nonadherence to the study protocol. Only one patient in the 
topiramate group withdrew because of adverse events, which 
consisted of paresthesia and confusion, probably due to the 
patient taking the wrong dose of medication (the exact dose 
was not reported in the article). The adverse events most 
commonly reported by patients receiving topiramate were 
paresthesia (48.6%), taste disturbance (24.3%), dysuria 
(13.5%), and leg pain (10,8%). The authors highlight the 
efficacy of the combination of topiramate and CBT in 
producing weight reduction and significant remission in 
bingeing in obese patients with BED.
Open-label studies
Appolinario and colleagues17 described the effects of 
topiramate on a woman diagnosed with BED in the absence 
of neuropsychiatric comorbidity. This woman had reported 
engaging in eight binge episodes each week and had previously 
been treated with amphetamine-like drugs, fluoxetine, and 
sibutramine without benefit. The initial topiramate dose was 
25 mg bid for 2 weeks, followed by an increase of 25 mg 
every week until she reached the target dose of 75 mg bid, 
which was maintained for 4 months. After the first 2 weeks of 
treatment, weekly binge eating decreased from 8 to 1, and the 
episodes completely remitted within 30 days of the onset of 
treatment. Her respective weight and BMI, which were 109 kg 
and 42.5 kg/m2 before starting treatment, decreased to 98.6 kg 
and 38.5 kg/m2 after 4 months of treatment. The only reported 
side effect was somnolence at the beginning of treatment. The 
authors did not use rating scales or standardized measures.Neuropsychiatric Disease and Treatment 2009:5 390
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Schmidt do Prado-Lima and Bacaltchuck18 described the 
topiramate treatment of a patient with refractory unipolar 
depression and comorbid BED. Topiramate was added to a 
drug regimen consisting of methylphenidate (20 mg/day) and 
venlafaxine (150 mg/day), and was titrated upward until a 
dose of 300 mg/day was reached. The patient experienced a 
remission in binge eating and a significant improvement in 
mood. Because this study used a single case characterized 
by comorbidity and polypharmacy, the results are difficult 
to generalize.
Appolinario and colleagues19 assessed the efficacy 
and tolerability of topiramate in a group of obese binge 
eaters with no neuropsychiatric comorbidity in a 16-week, 
open-label study. The study sample included eight female 
outpatients with a BMI  30, a diagnosis of BED according 
to DSM-IV criteria, and at least moderately severe binge 
eating behavior, defined as a BES score of  17. The dose 
of topiramate was gradually increased in weekly increments 
of 25 mg from 25 mg twice daily during the first 2 weeks 
to the target dosage of 75 mg twice daily at 2 months. 
Outcome measures included the number of days per week 
containing binge eating episodes (DBEs), BES scores, scores 
on the BDI, body weight, and adverse events. In reporting 
outcomes, an intent-to-treat analysis was employed. Of the 
eight patients enrolled in the study, 6 had attended all 
scheduled visits, 4 patients displayed a total remission 
of binge eating episodes, and 2 demonstrated a marked 
reduction in binge frequency. Two patients discontinued 
the trial, 1 because of diurnal somnolence at visit two 
and 1 due to lack of efficacy at week 6. Reported side 
effects were transient and included paresthesia (the most 
common, experienced by 4 patients), fatigue, somnolence, 
psychomotor slowing, impaired concentration, and nausea. 
All patients who completed the trial showed a reduction 
in binge eating (DBEs were reduced from 4.3 ± 1.7 to 
1.1 ± 2.4, P = 0.03; BES scores decreased from 31.8 ± 7.5 
to 15.3 ± 9.2, P = 0.04); a statistically significant weight 
loss was observed (mean 4.1 kg, P = 0.04) and depressive 
symptoms decreased significantly (mean BDI scores declined 
from 25.3 ± 7.5 to 15.8 ± 5.7, P = 0.02). The authors 
concluded that topiramate was effective in reducing eating 
psychopathology. Limitations of this study are its open-
label design, small sample size, and the impossibility of 
distinguishing between response to treatment and placebo 
effects, which is known to be quite high in BED.
Zilberstein and colleagues20 reported on the use of 
topiramate for BED in 16 patients who stopped losing 
weight after adjustable gastric banding. Topiramate was 
given in doses varying from 12.5 to 50 mg/day. The authors 
reported a mean increase in weight loss from 20.4% to 
34.1% in 14 patients after 90 days, without the need for band 
readjustment. Two patients were reported to have intolerance 
to topiramate; no further details were provided about the 
kinds of symptoms experienced.
Other anecdotal observations on the use of topiramate 
in three patients who underwent bariatric surgery were 
reported by Guerdjikova and colleagues.21 These patients 
gained weight and showed recurrent binge eating after 
initially successful bariatric surgery. The dose of topiramate 
prescribed ranged from 175 to 1000 mg/day. They reported 
remission of binge eating and displayed significant weight 
loss (31.7 kg, 14.5 kg, and 2 kg in 17, 9, and 4 months, 
respectively).
Conclusions and future directions
The existing literature appears to suffer from some 
limitations. The first concern that emerges from analyzing 
studies on the use of topiramate for BED is the long-term 
effects of this treatment. Obesity is known to be a chronic 
health problem, and long-term relapses after initial weight 
loss are known to be frequent; nevertheless, only one of the 
controlled studies reviewed15 involved long-term follow-up 
(42 weeks). This suggests caution in interpreting data, as the 
effects of long-term treatment with topiramate have not been 
extensively investigated.
A second limitation of the studies reviewed is the fairly 
high dropout rate of up to 30%. Adverse events have been 
discussed as a cause of patient dropout, but other causes 
(eg, protocol nonadherence) have not been discussed 
extensively. The acceptability of drug treatment by BED 
patients probably depends on many factors, among which 
the expectations of patients and motivation to change are 
likely to play a major role. It is noteworthy that completion 
rates were higher in the study of Claudino and colleagues16 
in which CBT was part of the study design. Appropriate 
strategies (counseling and psychotherapy) should be tested 
for their effectiveness in leading patients to more realistic 
weight loss goals and in sustaining motivation for drug 
adherence and lifestyle change.
A third issue is in regard to the wide exclusion criteria 
used by most RCTs. Frequent comorbidity (such as severe 
depression, bipolar disorder, or personality disorders) 
may lower the likelihood of remission of binge eating 
in the broad population of binge eaters compared to that 
of the patients considered in the trials described here. On the 
other hand, comorbidity can also provide indications that Neuropsychiatric Disease and Treatment 2009:5 391
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are valuable for targeting the pharmacological treatment 
to the needs of the individual patient (eg, treating a patient 
having bipolar symptoms with a mood stabilizer instead 
of an antidepressant) and should therefore be addressed in 
clinical research.
Another element that creates some difficulty in the 
interpretation of available data is the lack of homogeneity 
in psychological testing for the assessment of binge eating. 
Scales used in the studies reviewed include the Eating 
Disorder Inventory, second edition (EDI-2), BES, and 
YBOCS-BE. A consensus on which assessment tool should 
be used would add to the comparability of the published 
studies.
Note that two of the three RCTs were sponsored by 
the manufacturer of topiramate; these two studies reported 
better results for topiramate than placebo in reducing binge 
eating, whereas the third RCT did not find a significant effect 
for this drug. These results should be replicated by other 
independent studies to provide further evidence for the use 
of topiramate in BED.
A final limitation is in regard to subthreshold binge 
eaters. Some authors have contended that patients who feel a 
subjective sense of loss of control over eating might present 
with a level of distress and functional impairment that is 
comparable to that characteristic of eating disorders, even 
if they do not eat large amounts of food in a discrete period 
of time, as required by the DSM-IV-TR definition of a binge 
episode.22 This category of patients is probably subject to the 
same hazards to health and well-being as those who satisfy 
all the criteria for BED. Although these patients constitute 
a large proportion of overweight patients who fail several 
diet regimens and attend visits with nutritionists and eating 
disorders centers, indications about the role of psychophar-
macological treatment in this population are just beginning 
to emerge.23
In conclusion, topiramate appears to be a relatively safe 
and effective treatment for obese subjects with BED. The 
drug should probably be started at 25 mg/day and increased 
by 25 mg/day every 1 to 2 weeks, until reaching a dose of 
150 to 200 mg/day. It could then be further increased up to 
a dose of 400 mg/day or more for selected patients in the 
absence of clinical response.
Graphic representations of responses shown in the most 
comprehensive studies revealed that clinically significant 
changes in binge eating days per week and binge eating 
episodes per week should be expected after about 4 weeks 
of treatment, whereas effects on weight might be expected 
after approximately 6 to 8 weeks.
Topiramate appears to have a weight loss effect greater 
than those of other effective and well studied treatments 
for this disorder such as CBT, interpersonal therapy, and 
SSRIs, and one comparable to that of sibutramine.13 As noted 
above, depressive symptoms are frequently associated with 
BED, but as yet no compelling evidence exists of the efficacy 
of topiramate on this symptom dimension. This is partly a 
consequence of excluding patients with severe comorbid 
psychopathology from BED trials. The presence of moderate 
to severe depressive symptoms might be an indication for 
antidepressant treatment for binge eating patients.
Some authors have raised doubts about the tolerability 
of topiramate, drawing on data from the epilepsy literature; 
however, the dosages used in BED patients seem to lead to 
a somewhat milder adverse effect profile. The risk of kidney 
stones has been associated with this drug, but no cases of 
this adverse effect have been reported in obese patients 
with BED. Topiramate has been included in risk category 
3 regarding its use in pregnancy. This means that some animal 
studies have shown adverse effects; no controlled studies in 
humans have been conducted, although some case reports of 
hypospadia in male infants whose mothers took topiramate 
during pregnancy have been reported.
In this context, the use of topiramate in women with 
childbearing potential should be decided after weighing the 
potential benefits to the mother against the potential risks to the 
fetus. Further research is required regarding the long-term effects 
and the optimal dosing in BED patients. It will also be relevant 
to perform direct comparisons of the benefits and adverse 
effects of topiramate with those of other drugs that have been 
shown to be effective in reducing both binge eating and body 
weight in controlled trials, such as sibutramine, zonisamide, 
and atomoxetine. Future studies should focus on the indications 
for and effects of pharmacotherapy and evidence-based 
psychological treatments (such as CBT) for eating disorders 
as both separate and as combined interventions because the 
optimal management of BED can be achieved only with a 
multidisciplinary and multimodal treatment approach.24 One of 
the studies reviewed provides a model for this approach.16
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